Memantine in the treatment of mild-to-moderate Alzheimer’s disease

Cosman, Kelly M; Boyle, Lisa L.; Porsteinsson, Anton P.

doi:10.1517/14656566.8.2.203

Cited by 52 publications

(33 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Glutamate or free radicals, triggers of neuronal injury in AD (Smith et al, 2000;Li et al, 2004;Moreira et al, 2005;Cosman et al, 2007), may play a central role in inducing ER stress in AD. Activation of glutamate receptors sensitive to NMDA results in excess accumulation of Ca 2+ in neurons that can induce free radical production and ER stress (Dugan et al, 1995;Reynolds and Hastings, 1995;Liu et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

“…Activation of glutamate receptors sensitive to NMDA results in excess accumulation of Ca 2+ in neurons that can induce free radical production and ER stress (Dugan et al, 1995;Reynolds and Hastings, 1995;Liu et al, 1998). It is of note that memantine, a partial NMDA receptor antagonist, is approved for treating moderate-to-severe AD patients (Li et al, 2004;Cosman et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Induction of the unfolded protein response and cell death pathway in Alzheimer's disease, but not in aged Tg2576 mice

et al. 2010

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Induction of the unfolded protein response and cell death pathway in Alzheimer's disease, but not in aged Tg2576 mice

et al. 2010

View full text Add to dashboard Cite

“…The feasibility of this approach is, in part, supported by the broad peripheral distribution of these receptors. For example, MORs are present in a number of peripheral tissues, including the small and large intestines, kidney, lung, spleen, testis, ovaries and uterus (97). While these sites are important in mediating a number of physiologic processes, molecular and functional studies suggest that MORs and NMDA receptors localized on unmyelinated, cutaneous sensory axons contribute to antinociception (98).…”

Section: The Role Of Peripheral Opioid and Nmda Receptors In Mediatinmentioning

confidence: 99%

Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective

Dumas

Pollack

2008

AAPS J

231

164

View full text Add to dashboard Cite

Abstract. The opioids are commonly used to treat acute and severe pain. Long-term opioid administration eventually reaches a dose ceiling that is attributable to the rapid onset of analgesic tolerance coupled with the slow development of tolerance to the untoward side effects of respiratory depression, nausea and decreased gastrointestinal motility. The need for effective-long term analgesia remains. In order to develop new therapeutics and novel strategies for use of current analgesics, the processes that mediate tolerance must be understood. This review highlights potential pharmacokinetic (changes in metabolite production, metabolizing enzyme expression, and transporter function) and pharmacodynamic (receptor type, location and functionality; alterations in signaling pathways and crosstolerance) aspects of opioid tolerance development, and presents several pharmacodynamic modeling strategies that have been used to characterize time-dependent attenuation of opioid analgesia.

show abstract

“…Hence, using NMDA antagonists would be an efficient way to prevent RGC loss. Memantine is a promising neuroprotective agent and has been approved for use on patients with moderate to severe Alzheimer`s disease by the US Food and Drug Administration [100,101]. Memantine is a NMDA receptor blocker and may prevent excitotoxic cell death of damaged RGCs [100,101].…”

Section: N-methyl-d-aspartate (Nmda) Receptor Antagonistsmentioning

confidence: 99%

Diabetes Mellitus and Retinal Vein Occlusion as Risk Factors for Open Angle Glaucoma and Neuroprotective Therapies for Retinal Ganglion Cell Neuropathy

Bikbova¹,

Oshitari²,

Yamamoto³

2011

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

of glaucoma (NTG), and the prevalence of NTG is 3.6% in patients >40-years-of-age in Japan [10]. The average intraocular pressure (IOP) in patients with POAG is 15.4 ± 2.8 mmHg, which is significantly higher than that of normal subjects (14.5 ± 2.5 mmHg) [1][2][3][4][5][6][7][8][9][10] even though the average difference in the IOP is only 0.9 mmHg. Thus, a reduction of the IOP the standard therapy for glaucoma may not be sufficient for the complete management of the patients with glaucoma in Japan. Other therapeutic modalities, such as neuroprotection, should be considered for a complete therapeutic regimen for glaucoma patients.RGC death and axonal degeneration are most likely involved in the progression of DR, RVO, and glaucoma. Many neuroprotective therapies that prevent RGC death and axonal degeneration have been and are being investigated, and some of these neuroprotective factors may be used clinically in the near future. To establish neuroprotective therapies for DR, RVO and glaucoma, a determination of the exact mechanism that leads to a progression of RGC neuropathy to death and axonal degeneration is required [11]. However, the pathogenesis of the onset and progression of RGC neuropathy has still not been definitively determined. Identification of the risk factors for the onset and the progression of disease would help in determining the Abstract Glaucoma, diabetic retinopathy (DR), and retinal vein occlusion (RVO) are major diseases that can lead to blindness and affect mainly the elderly population worldwide. The results of recent investigations have demonstrated that the death of retinal ganglion cells (RGCs) and their axons is the common pathological change in these three disease processes. The exact mechanism that is responsible for the onset and progression of RGC death and axonal degeneration in patients with glaucoma, DR and RVO has not been definitively determined. Thus, identifying the risk factors for the onset and the progression of RGC neuropathy can help in deciding not only the specific treatments but also whether the treatments should be initiated, withheld, or augmented in individuals with glaucoma, DR, and RVO. This review describes the major risk factors for the onset of glaucoma, and the factors associated with the progression of glaucoma that have been obtained from large population-based prevalence and incidence studies. In addition, the potential risk factors for glaucoma, diabetes mellitus, and RVO are discussed in terms of the results obtained by both clinical and laboratory studies. This review introduces potential neuroprotective therapies for damaged RGC in eyes with RGC neuropathy, and the factors that should be considered for a complete therapy for the RGC neuropathy involved in glaucoma, DR and RVO. Neuroprotective therapies combined with a reduction of the IOP should be considered for the complete management of RGC neuropathy involved in glaucoma,

show abstract

Memantine in the treatment of mild-to-moderate Alzheimer’s disease

Cited by 52 publications

References 58 publications

Induction of the unfolded protein response and cell death pathway in Alzheimer's disease, but not in aged Tg2576 mice

Induction of the unfolded protein response and cell death pathway in Alzheimer's disease, but not in aged Tg2576 mice

Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective

Diabetes Mellitus and Retinal Vein Occlusion as Risk Factors for Open Angle Glaucoma and Neuroprotective Therapies for Retinal Ganglion Cell Neuropathy

Contact Info

Product

Resources

About